alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<RESTATED> 
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                           1,471
<SECURITIES>                                     9,899
<RECEIVABLES>                                   13,803
<ALLOWANCES>                                       881
<INVENTORY>                                      8,404
<CURRENT-ASSETS>                                33,361
<PP&E>                                           7,377
<DEPRECIATION>                                   4,270
<TOTAL-ASSETS>                                  36,937
<CURRENT-LIABILITIES>                           10,154
<BONDS>                                             64
<PREFERRED-MANDATORY>                           42,891
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                     (16,172)
<TOTAL-LIABILITY-AND-EQUITY>                    36,937
<SALES>                                         11,565
<TOTAL-REVENUES>                                11,565
<CGS>                                            7,441
<TOTAL-COSTS>                                    7,441
<OTHER-EXPENSES>                                 4,664
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  31
<INCOME-PRETAX>                                   (383)
<INCOME-TAX>                                         6
<INCOME-CONTINUING>                               (389)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                      (389)
<EPS-PRIMARY>                                    (0.04)
<EPS-DILUTED>                                    (0.04)
        


</TABLE>
Exhibit
32.2





Certification
of Chief Financial Officer


Pursuant
to 18 U.S.C. Section 1350,


as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002





In
connection with the quarterly report of Axion International Holdings, Inc. (the
“Company”) on Form 10-Q for the quarter ended June 30, 2010 as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), I, Michael
W. Johnson, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002,
that:





(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and





(2)
The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the
Company.





/s/
      Gary AnthonyGary
      AnthonyChief
      Financial OfficerAugust
      16, 2010
Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. 1350 AS ADOPTED PURSUANT TO SECTION 906

OF THE
SARBANES-OXLEY ACT OF 2002

Solely for the purpose of complying with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, we, the undersigned Chief Executive Officer and Chief Financial Officer of Manitex International, Inc. (the Company), hereby certify that, to the best of our knowledge, the Annual Report of the Company on Form
10-K for the year ended December 31, 2008 (the Report) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the Company.



|       |  |                                                             
|------ |  | ------------------------------------------------------------
|By:    |  | /s/    DAVID J.
LANGEVIN                                    
|Name:  |  | David J. Langevin                                           
|Title: |  | Chairman and Chief Executive Officer                        
|       |  | (Principal Executive Officer of Manitex International, Inc.)

Dated: March 30, 2010



|       |  |                                                                            
|------ |  | ---------------------------------------------------------------------------
|By:    |  | /s/    DAVID H.
GRANSEE                                                    
|Name:  |  | David H. Gransee                                                           
|Title: |  | Vice President and Chief Financial Officer                                 
|       |  | (Principal Financial and Accounting Officer of Manitex International, Inc.)

Dated: March 30, 2010
---

Exhibit 13.2

CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO 
SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

I, Martin B. Carsky, hereby certify, pursuant to 18 U.S.C.
§1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:

| | (i)  | the Annual Report on Form 20-F of Great Panther Silver
      Limited for the year ended December 31, 2011 (the Report), as filed with
      the Securities and Exchange Commission, fully complies with the
      requirements of Section 13(a) or 15(d), as applicable, of the Securities
      Exchange Act of 1934; and
| | ---- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |      |                                                                                                                                                                                                                                                                                                                             
| | (ii) | the information contained in the Report fairly presents,
      in all material respects, the financial condition and results of
      operations of Great Panther Silver Limited.                                                                                                                                           

|Date: March 14, 2012 | /s/
      Martin B. Carsky   
|-------------------- | -----------------------------
|                     | Martin B. Carsky             
|                     | Chief Financial Officer      
|                     | (Principal Financial Officer)

A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the
signature that appears in typed form within the electronic version of this
written statement required by Section 906, has been provided to Great Panther
Silver Limited and will be retained by Great Panther Silver Limited and
furnished to the Securities and Exchange Commission or its staff upon
request.

---
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 2675 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 2675

     To suspend temporarily the duty on Ancamine 2422 Curing Agent.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 7, 2012

   Mr. Casey introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
     To suspend temporarily the duty on Ancamine 2422 Curing Agent.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ANCAMINE 2422 CURING AGENT.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``     9902.01.00      Modified aliphatic  Free         No change        No change        On or before 12/  ''.
                        polyamine mixture                                                  31/2015.......
                        of reaction
                        products of 1,3-
                        bis(aminomethyl)b
                        enzene with
                        phenol and
                        formaldehyde and
                        1,3-
                        bis(aminomethyl)b
                        enzene (provided
                        for in subheading
                        3909.30.00)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```
Fourth Court of Appeals

San Antonio, Texas

MEMORANDUM OPINION

No. 04-15-00224-CR

Julio Alejandro ZUNIGA,

Appellant

v.

The STATE of Texas,

Appellee

From the 187th Judicial District Court, Bexar County, Texas

Trial Court No. 2014CR0936-W1

Honorable Raymond Angelini, Judge Presiding

PER CURIAM

Sitting: Patricia O. Alvarez, Justice

Luz Elena D. Chapa, Justice

Jason Pulliam, Justice

Delivered and Filed: June 3, 2015

DISMISSED FOR WANT OF JURISDICTION

On May 18, 2015, this court issued an order directing Appellant Julio Alejandro Zuniga to 

show cause why this appeal should not be dismissed for want of jurisdiction. Appellant responded 

that his April 13, 2015 pro se notice of appeal was erroneously filed in District Court cause number

2014CR0936-W1 instead of cause number 2014CR0936. Because the Court of Criminal Appeals 

already granted the relief Appellant sought in District Court cause number 2014CR0936-W1, 
04-15-00224-CR

- 2 -

Appellant conceded that the appeal filed in this court as cause number 04-14-00224-CR should be 

dismissed. Accordingly, this appeal is DISMISSED.

PER CURIAM

DO NOT PUBLISH
II 

112TH CONGRESS 

2D SESSION S. 2620 

To amend title XVIII of the Social Security Act to provide for an extension 

of the Medicare-dependent hospital (MDH) program and the increased 

payments under the Medicare low-volume hospital program. 

IN THE SENATE OF THE UNITED STATES 

MAY 7, 2012 

Mr. SCHUMER (for himself and Mr. GRASSLEY) introduced the following bill; 

which was read twice and referred to the Committee on Finance 

A BILL 

To amend title XVIII of the Social Security Act to provide 

for an extension of the Medicare-dependent hospital 

(MDH) program and the increased payments under the 

Medicare low-volume hospital program. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Rural Hospital Access 

5 Act of 2012’’. 


jbell on DSK7SPTVN1PROD with BILLS
2 

•S 2620 IS

1 SEC. 2. EXTENSION OF THE MEDICARE-DEPENDENT HOS2 PITAL (MDH) PROGRAM. 

3 (a) EXTENSION OF PAYMENT METHODOLOGY.—Sec4 tion 1886(d)(5)(G) of the Social Security Act (42 U.S.C. 

5 1395ww(d)(5)(G)) is amended— 

6 (1) in clause (i), by striking ‘‘October 1, 2012’’ 

7 and inserting ‘‘October 1, 2013’’; and 

8 (2) in clause (ii)(II), by striking ‘‘October 1, 

9 2012’’ and inserting ‘‘October 1, 2013’’. 

10 (b) CONFORMING AMENDMENTS.— 

11 (1) EXTENSION OF TARGET AMOUNT.—Section 

12 1886(b)(3)(D) of the Social Security Act (42 U.S.C. 

13 1395ww(b)(3)(D)) is amended— 

14 (A) in the matter preceding clause (i), by 

15 striking ‘‘October 1, 2012’’ and inserting ‘‘Oc16 tober 1, 2013’’; and 

17 (B) in clause (iv), by striking ‘‘through fis18 cal year 2012’’ and inserting ‘‘through fiscal 

19 year 2013’’. 

20 (2) PERMITTING HOSPITALS TO DECLINE RE21 CLASSIFICATION.—Section 13501(e)(2) of the Omni22 bus Budget Reconciliation Act of 1993 (42 U.S.C. 

23 1395ww note) is amended by striking ‘‘through fis24 cal year 2012’’ and inserting ‘‘through fiscal year 

25 2013’’. 


jbell on DSK7SPTVN1PROD with BILLS
3 

•S 2620 IS

1 SEC. 3. EXTENSION OF THE INCREASED PAYMENTS UNDER 

2 THE MEDICARE LOW-VOLUME HOSPITAL 

3 PROGRAM. 

4 Section 1886(d)(12) of the Social Security Act (42 

5 U.S.C. 1395ww(d)(12)) is amended— 

6 (1) in subparagraph (B), in the matter pre7 ceding clause (i), by striking ‘‘2013’’ and inserting 

8 ‘‘2014’’; 

9 (2) in subparagraph (C)(i), by striking ‘‘and 

10 2012’’ each place it appears and inserting ‘‘, 2012, 

11 and 2013’’; and 

12 (3) in subparagraph (D), by striking ‘‘and 

13 2012’’ and inserting ‘‘, 2012, and 2013’’. 

Æ 


jbell on DSK7SPTVN1PROD with BILLS
II 

112TH CONGRESS 

2D SESSION S. 2838 

To extend and modify the temporary reduction of duty on viscose rayon 

staple fibers having a decitex of less than 5.0. 

IN THE SENATE OF THE UNITED STATES 

MAY 7, 2012 

Ms. COLLINS introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To extend and modify the temporary reduction of duty on 

viscose rayon staple fibers having a decitex of less than 

5.0. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. VISCOSE RAYON STAPLE FIBERS HAVING A 

4 DECITEX OF LESS THAN 5.0. 

5 (a) IN GENERAL.—Heading 9902.55.04 of the Har6 monized Tariff Schedule of the United States (relating to 

7 viscose rayon staple fibers having a decitex of less than 

8 5.0) is amended— 

9 (1) by striking ‘‘1.8%’’ in the column 1 general 

10 rate of duty column and inserting ‘‘1.3%’’; and 


jbell on DSK7SPTVN1PROD with BILLS
2 

•S 2838 IS

1 (2) by striking the date in the effective period 

2 column and inserting ‘‘12/31/2015’’. 

3 (b) EFFECTIVE DATE.—The amendments made by 

4 subsection (a) apply with respect to goods entered, or 

5 withdrawn from warehouse for consumption, on or after 

6 the 15th day after the date of the enactment of this Act. 

Æ 


jbell on DSK7SPTVN1PROD with BILLS
# Official Journal C 337/26 S

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 337 |
| | |
| English edition | Information and Notices | Volume 5726 September 2014 |

ISSN 1977-091X

Official Journal

of the European Union

C 337

English edition

Information and Notices

Volume 5726 September 2014

---

| Notice No | Contents | page |
| --- | --- | --- |
| | IV   Notices |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2014/C 337/01 | Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2014 to 31 July 2014(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council) | 1 |
| 2014/C 337/02 | Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 August 2014 to 31 August 2014(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council) | 4 |
| 2014/C 337/03 | Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 August 2014 to 31 August 2014(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC) | 12 |

Notice No

Contents

page

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2014/C 337/01

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2014 to 31 July 2014(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

1

2014/C 337/02

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 August 2014 to 31 August 2014(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

4

2014/C 337/03

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 August 2014 to 31 August 2014(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

12

---

| EN | |
| --- | --- |

EN
```
Cendant Mortgage Corporation  Mortgage Pass-Through Certificates,
Series 2004-5
```

```
Schedule of Year-To-Date Principal and Interest Distributions to
Certificateholders for 2004
```

```
Class   Interest            Principal PaidRealized    Ending Balance
        Distribution                      Losses
```

```
A1      266,053.30          6,630,914.70  0.00        12,701,141.30
A2      223,795.20          0.00          0.00        22,752,055.00
A3      277,673.71          0.00          0.00        25,046,645.00
A4      219,510.42          0.00          0.00        14,795,533.00
A5      0.00                0.00          0.00        12,551,704.78
A6      0.00                0.00          0.00        2,695,340.99
A7      0.00                0.00          0.00        1,806,543.09
A8      0.00                0.00          0.00        14,764,040.49
B1      79,340.89           15,259.64     0.00        5,337,572.36
B2      11,589.11           2,228.94      0.00        779,645.06
B3      6,240.30            1,200.19      0.00        419,808.81
B4      3,565.88            685.83        0.00        239,891.17
B5      2,674.42            514.37        0.00        179,918.63
B6      3,565.88            685.83        0.00        239,890.62
RI      0.49                100.00        0.00        0.00
RII     0.49                100.00        0.00        0.00
```
Z.B., a child, Appellant, v. STATE of Florida, Appellee.

No. 4D17-0089

District Court of Appeal of Florida, Fourth District.

[March 1, 2018]

**DECISION WITHOUT PUBLISHED OPINION**

*Affirmed.*
T.C.K. v. LEE COUNTY DEPARTMENT OF HUMAN RESOURCES

2150943

Court of Civil Appeals of Alabama.

January 13, 2017 Reh. denied February 24, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
exhibit10_14.htm


    
      

      

    


    Exhibit
10.14

    


    FIRST AMENDMENT TO
APPLETON PAPERS
INC.

    TERMINATION PROTECTION
AGREEMENT

    


    


    This
First Amendment (“Amendment”) to the Appleton Papers Inc. Termination Protection
Agreement effective April 4, 2005 (“Agreement”) is made by and among Appleton
Papers Inc. (the “Corporation”) and Mark R. Richards (the
“Executive”).  The terms and conditions of this Amendment are as
follows:

    


    1.           Paragraph
3(b)(i) of the Agreement shall be deleted in its entirety and replaced with the
following:

    


    an amount
in cash equal to the product of three (3), multiplied by the sum of the
Executive’s Base Salary and Target Bonus;

    


    2.           This
Amendment is effective upon execution and hereby becomes part of the
Agreement.

    


    3.           Except
as expressly modified herein, the Agreement between the Corporation and the
Executive shall remain unchanged and in full force and effect.

    


    IN WITNESS WHEREOF, the parties have
executed this Amendment, dated as of January 4, 2008.

    


    APPLETON PAPERS INC.

    


    


    


    By:              /s/ Angela
M. Tyczkowski

    Angela M. Tyczkowski,
Secretary

    For the Board of
Directors

    


    


    EXECUTIVE

    


    


    By:              /s/ Mark
R. Richards

    Mark R. Richards

    CEO and President
II 

112TH CONGRESS 

2D SESSION S. 2462 

To renew and modify the temporary reduction of duty on certain low 

expansion laboratory glassware. 

IN THE SENATE OF THE UNITED STATES 

APRIL 26, 2012 

Mr. SCHUMER introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To renew and modify the temporary reduction of duty on 

certain low expansion laboratory glassware. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. CERTAIN LOW EXPANSION LABORATORY 

4 GLASSWARE. 

5 (a) IN GENERAL.—Heading 9902.12.39 of the Har6 monized Tariff Schedule of the United States (relating to 

7 certain low expansion laboratory glassware) is amended— 

8 (1) in the article description, by striking 

‘‘10¥7’’ and inserting ’’ and inserting ‘‘10¥6 9 ’’; and 

mstockstill on DSK4VPTVN1PROD with BILLS

2 

•S 2462 IS 

1 (2) by striking the date in the effective period 

2 column and inserting ‘‘12/31/2015’’. 

3 (b) EFFECTIVE DATE.—The amendments made by 

4 subsection (a) apply with respect to goods entered, or 

5 withdrawn from warehouse for consumption, on or after 

6 the 15th day after the date of the enactment of this Act. 

Æ 

mstockstill on DSK4VPTVN1PROD with BILLS
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 2870 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 2870

        To extend the temporary suspension of duty on 2-(4-Tert-
 butylphenoxy)cyclohexylprop-2-ynyl sulfite (Propargite) (CAS No. 2312-
                                 35-8).

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 8, 2012

   Mr. Pryor introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
        To extend the temporary suspension of duty on 2-(4-Tert-
 butylphenoxy)cyclohexylprop-2-ynyl sulfite (Propargite) (CAS No. 2312-
                                 35-8).

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. 2-(4-TERT-BUTYLPHENOXY)CYCLOHEXYLPROP-2-YNYL SULFITE 
              (PROPARGITE) (CAS NO. 2312-35-8).

    (a) In General.--Heading 9902.25.09 of the Harmonized Tariff 
Schedule of the United States (relating to 2-(4-Tert-
butylphenoxy)cyclohexylprop-2-ynyl sulfite (Propargite) (CAS No. 2312-
35-8)) is amended by striking the date in the effective period column 
and inserting ``12/31/2015''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```